Ondine Biomedical (LSE:OBI) 3-Year Revenue Growth Rate : 26.00% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical 3-Year Revenue Growth Rate?

Ondine Biomedical's Revenue per Share for the six months ended in Jun. 2023 was £0.00.

During the past 12 months, Ondine Biomedical's average Revenue per Share Growth Rate was -33.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 26.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 48.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was -19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Ondine Biomedical was 166.80% per year. The lowest was -79.70% per year. And the median was 48.50% per year.

Competitive Comparison of Ondine Biomedical's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Ondine Biomedical's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ondine Biomedical's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's 3-Year Revenue Growth Rate falls into.

Ondine Biomedical 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Ondine Biomedical (LSE:OBI) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Ondine Biomedical 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ondine Biomedical (LSE:OBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (LSE:OBI) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

OBIMF:USA

Address

1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6

Website

https://www.ondinebio.com

Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical (LSE:OBI) Headlines

No Headlines